Scarica l'app Stockscreener
32.98
1.82%
0.59
Dopo l'orario di chiusura:
31.81
-1.17
-3.55%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$32.39
Aprire:
$33.13
Volume 24 ore:
910.76K
Relative Volume:
0.78
Capitalizzazione di mercato:
$1.88B
Reddito:
$199.89M
Utile/perdita netta:
$52.48M
Rapporto P/E:
38.80
EPS:
0.85
Flusso di cassa netto:
$61.15M
1 W Prestazione:
-0.06%
1M Prestazione:
+24.41%
6M Prestazione:
+186.04%
1 anno Prestazione:
+173.47%
Intervallo 1D:
$32.47
$35.43
Intervallo di 1 settimana:
$30.17
$35.43
Portata 52W:
$5.35
$38.69
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Confronta STOK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
32.98 | 1.85B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-18 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $50.00 at HC Wainwright - MarketBeat
STOK: HC Wainwright & Co. Raises Price Target to $50 | STOK Stoc - GuruFocus
(STOK) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Stoke Therapeutics: A Deep Dive into Clinical Progress and Market Sentiment - AD HOC NEWS
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? - AOL.com
Redmile Group LLC Cuts Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 3,978 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells $433,386.10 in Stock - MarketBeat
Insider Selling Alert: Kaye Edward M. MD Sells Shares of Stoke T - GuruFocus
Stoke Therapeutics Insider Sold Shares Worth $433,385, According to a Recent SEC Filing - marketscreener.com
Stoke Therapeutics (NASDAQ:STOK) Shares Up 12.4%Time to Buy? - MarketBeat
After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers - Nasdaq
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.1%What's Next? - MarketBeat
Marshall Wace LLP Acquires 168,771 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
With Stoke Therapeutics Stock Surging, Have You Considered The Downside? - Trefis
Stoke Therapeutics, Inc. $STOK Shares Purchased by Franklin Resources Inc. - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells $267,723.36 in Stock - MarketBeat
Jonathan Allan Sells 8,785 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 6,453 Shares - MarketBeat
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 1,018 Shares of Stock - MarketBeat
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 3,662 Shares - MarketBeat
Allan Jonathan of Stoke Therapeutics sells $306k in shares By Investing.com - Investing.com South Africa
Kaye Edward M. MD sells Stoke Therapeutics (STOK) stock for $467k - Investing.com India
Allan Jonathan of Stoke Therapeutics sells $306k in shares - Investing.com
Stoke Therapeutics Executives Conduct Multiple Stock Sales - TradingView — Track All Markets
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Fly 36% But Investors Aren't Buying For Growth - 富途牛牛
Biogen (BIIB) Advances Potential Treatment for Dravet Syndrome w - GuruFocus
Zorevunersen shows promise for Dravet syndrome in long-term data By Investing.com - Investing.com South Africa
Stoke Therapeutics Highlights Zorevunersen’s Potential at Epilepsy Meeting - TipRanks
Stoke Therapeutics and Biogen present data that further support the disease-modifying potential of zorevunersen - marketscreener.com
Stoke, Biogen Present Positive Long-Term Results For Zorevunersen In Dravet Syndrome - Nasdaq
Biogen and Stoke Therapeutics present data that further support the disease-modifying potential of zorevunersen - marketscreener.com
Stoke Therapeutics, Inc. and Biogen Present Data on Zorevunersen at AES 2025 - TradingView — Track All Markets
Biogen and Stoke Therapeutics Present Promising Long-term Data for Zorevunersen in Treating Dravet Syndrome at AES 2025 - Quiver Quantitative
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - The Manila Times
Biogen (Nasdaq: BIIB) and Stoke share long-term Dravet data on zorevunersen - Stock Titan
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry - simplywall.st
Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 1,066 Shares - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $61,729.10 in Stock - MarketBeat
Stoke Therapeutics: A Long-Term Biotech Growth PlayWhy I Assign A Hold Rating (STOK) - Seeking Alpha
Geode Capital Management LLC Has $11.04 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 2,292 Shares of Stock - MarketBeat
Kaye Edward M. MD sells Stoke Therapeutics (STOK) shares for $64,541 By Investing.com - Investing.com South Africa
Kaye Edward M. MD sells Stoke Therapeutics (STOK) shares for $64,541 - Investing.com Nigeria
Can Stoke Therapeutics Inc. stock beat analyst upgradesJuly 2025 Sector Moves & Risk Managed Trade Strategies - Newser
Does Stoke Therapeutics Still Make Sense After Its 2025 Rally And Lofty Valuation Multiples? - simplywall.st
A Look at Stoke Therapeutics (STOK) Valuation After a 167% Year-to-Date Surge - Yahoo Finance
Price-Driven Insight from (STOK) for Rule-Based Strategy - news.stocktradersdaily.com
Biogen and Stoke Therapeutics Present Promising Zorevunersen Data for Dravet Syndrome at 2025 American Epilepsy Society Annual Meeting - Quiver Quantitative
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):